Jan 8, 2026 02:16AM
Sep 23, 2025 02:29AM
Aug 13, 2025 01:00AM
Jan 14, 2025 01:00AM
Jan 6, 2025 01:00AM
Oct 1, 2024 01:00AM
Sep 12, 2024 01:00AM Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update
Jun 18, 2024 01:15AM
Jun 10, 2024 01:00AM
Apr 25, 2024 01:00AM
Dec 18, 2023 01:00AM
Jul 31, 2023 01:00AM
Jun 29, 2023 01:00AM
May 31, 2023 05:50PM Santhera Publishes Annual Report 2022
Apr 27, 2023 01:00AM
Apr 25, 2023 01:00AM
Mar 2, 2023 01:00AM
Feb 28, 2023 01:00AM
Feb 8, 2023 01:00AM
Jan 10, 2023 01:00AM
Jan 9, 2023 01:00AM Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy
Nov 29, 2022 05:45AM
Nov 4, 2022 02:00AM
Oct 31, 2022 02:05AM
Oct 31, 2022 02:00AM
Oct 27, 2022 01:00AM
Oct 10, 2022 01:00AM
Oct 3, 2022 01:00AM Santhera Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy
Sep 29, 2022 01:00AM
Sep 1, 2022 01:00AM
Aug 22, 2022 01:00AM
Jun 30, 2022 11:45AM
Jun 29, 2022 01:00AM
Jun 27, 2022 02:25PM
Jun 10, 2022 01:00AM Santhera Reports 2021 Annual Results
Jun 9, 2022 01:00AM
Jun 3, 2022 11:45AM
Jun 2, 2022 01:00AM
Apr 29, 2022 01:00AM
Apr 13, 2022 01:00AM
Mar 29, 2022 01:00AM
Mar 15, 2022 02:05AM Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
Mar 15, 2022 02:00AM
Mar 11, 2022 01:00AM
Feb 28, 2022 01:00AM
Feb 18, 2022 01:00AM
Jan 4, 2022 01:00AM
Dec 6, 2021 01:00AM
Nov 24, 2021 01:00AM Santhera Provides Corporate Update and Calls Extraordinary General Meeting to Seek Approval for Further Financings
Nov 23, 2021 01:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All